http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105603085-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105603085-B |
| titleOfInvention | The diagnosis and treatment target of intervertebral disk retrogression lesion |
| abstract | The invention discloses a kind of diagnosis and treatment target-TULP2 genes of intervertebral disk retrogression lesion.The present invention, which may determine that whether subject suffers from intervertebral disk retrogression lesion or diagnose subject by the content of TULP2 gene and its expression product in detection subject's disc tissue, whether there is the risk with intervertebral disk retrogression lesion.In addition, the present invention proves drug target of the TULP2 gene as treatment intervertebral disk retrogression lesion by the growth, aging, apoptosis index of the nucleus pulposus cell of research in vitro culture. |
| priorityDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.